Farringdon Capital, Ltd. Immunity Bio, Inc. Transaction History
Farringdon Capital, Ltd.
- $393 Billion
- Q3 2025
A detailed history of Farringdon Capital, Ltd. transactions in Immunity Bio, Inc. stock. As of the latest transaction made, Farringdon Capital, Ltd. holds 16,644 shares of IBRX stock, worth $34,619. This represents 0.01% of its overall portfolio holdings.
Number of Shares
16,644Holding current value
$34,619% of portfolio
0.01%Shares
1 transactions
Others Institutions Holding IBRX
# of Institutions
298Shares Held
137MCall Options Held
2.59MPut Options Held
3.35M-
Vanguard Group Inc Valley Forge, PA27.7MShares$57.5 Million0.0% of portfolio
-
Jane Street Group, LLC New York, NY12.8MShares$26.7 Million0.01% of portfolio
-
Black Rock Inc. New York, NY11.4MShares$23.8 Million0.0% of portfolio
-
State Street Corp Boston, MA11.3MShares$23.5 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA6.89MShares$14.3 Million0.0% of portfolio
About ImmunityBio, Inc.
- Ticker IBRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 400,304,000
- Market Cap $833M
- Description
- ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T cell) immune systems. The com...